CAPR

Business Context and Reporting Period

This Form 8-K, dated November 20, 2013, reports the completion of a merger between Nile Therapeutics, Inc. ("Nile") and Capricor, Inc. ("Capricor"). Following the transaction, Nile changed its name to Capricor Therapeutics, Inc. The filing details the consummation of the Merger Agreement, a 1-for-50 reverse stock split, and significant changes to the company's capital structure, executive leadership, and board of directors.

Key Financial and Capital Metrics

The filing does not provide revenue, profit, cash flow, or debt metrics, as it is a current report focused on corporate restructuring rather than financial performance. Key capitalization data includes:

• Post-Merger Ownership: Former Capricor stockholders own approximately 90% of the outstanding common stock; former Nile stockholders own approximately 10% (on a fully-diluted basis).
• Exchange Ratio: Each outstanding share of Capricor common stock was converted into the right to receive approximately 2.07 shares of Capricor Therapeutics common stock (post-split basis).
• Outstanding Shares: Approximately 11,687,835 shares of common stock issued and outstanding immediately following the merger.
• Dilutive Securities: Options and warrants exercisable for approximately 5,220,825 shares of common stock.
• Authorized Shares: Reduced to 50,000,000 common shares and 5,000,000 preferred shares.

Material Changes Versus Prior Period

The filing documents a fundamental transformation of the registrant:

• Corporate Identity: The company name changed from Nile Therapeutics, Inc. to Capricor Therapeutics, Inc.
• Stock Structure: A 1-for-50 reverse stock split was effected. The ticker symbol changed from "NLTX" to "NLTXD" (effective Nov 21, 2013) and will change to "CAPR" (effective Dec 20, 2013).
• Leadership Transition: Former Nile CEO Dr. Darlene Horton and CFO Daron Evans resigned. Dr. Linda Marbán was appointed CEO, and a new board of directors was elected, primarily composed of former Capricor directors.
• Agreement Terminations: Nile terminated a Services Agreement with Two River Consulting, LLC, and the employment agreements of Dr. Horton and Mr. Evans.

Compensatory Arrangements and Unregistered Sales

In connection with the merger and change of control:

• Dr. Horton: Received 77,208 shares of Capricor Therapeutics common stock (representing 5% of Nile's pre-merger fully-diluted shares) prior to the termination of her employment.
• Mr. Evans: Received 69,487 shares of Capricor Therapeutics common stock (representing 4.5% of Nile's pre-merger fully-diluted shares) prior to the termination of his employment.
• Assumed Options: Capricor Therapeutics assumed outstanding stock options from Capricor's 2006, 2012, and 2012 Restated Equity Incentive Plans, adjusting exercise prices and share counts to reflect the merger ratio and reverse split.

Guidance, Outlook, and Risks

The filing does not contain forward-looking financial guidance or management commentary regarding future revenue or profitability. The primary risks and contingencies noted relate to the corporate restructuring:

• Trading Suspension: Nile stock was suspended for trading on November 20, 2013, with new trading commencing under a different symbol.
• Unregistered Securities: Shares issued to former Capricor stockholders, Dr. Horton, and Mr. Evans were issued pursuant to exemptions from registration (Section 4(2) and Rule 506) and are subject to resale restrictions.
• Leadership Continuity: The departure of the entire prior Nile executive team and board introduces operational transition risks, though the new leadership team is experienced in the biopharmaceutical sector.

Investor Verification Checklist

• Verify the new ticker symbol "CAPR" and trading commencement date of December 20, 2013, on the OTC Markets.
• Confirm the exact number of shares held post-merger based on the 1-for-50 reverse split and the 2.07 exchange ratio for former Capricor shareholders.
• Review the Definitive Proxy Statement (Schedule 14A) filed October 10, 2013, for detailed biographical information on the new board and executive officers.
• Check the status of the assumed stock options and their adjusted exercise prices under the Capricor Therapeutics equity plans.
• Monitor future filings for the first consolidated financial statements reflecting the combined entity's liquidity and debt position.